Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 56 Ovarian Neoplasms 35 Carcinoma, Hepatocellular 35 Neoplasms 25 Fallopian Tube Neoplasms 20 Carcinoma, Non-Small-Cell Lung 19 Endometrial Neoplasms 13 Glioblastoma 11 Breast Neoplasms 11 Brain Neoplasms 11 Neoplasm Metastasis 9 Colonic Neoplasms 9 Lung Neoplasms 8 Uterine Cervical Neoplasms 7 Liver Neoplasms 7 Rectal Neoplasms 6 Glioma 6 Biliary Tract Neoplasms 6 Stomach Neoplasms 5 Triple Negative Breast Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Gastrointestinal Neoplasms 4 Digestive System Neoplasms 4 Carcinoma, Ovarian Epithelial 4 Small Cell Lung Carcinoma 3 Sarcoma 3 Recurrence 3 Peritoneal Neoplasms 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Pancreatic Neoplasms 3

Interventions

pembrolizumab 1 liposomal doxorubicin 1 Paclitaxel 1 Gemcitabine 1 Carboplatin 1 Bevacizumab 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Ovarian Cancer Recurrent × Bevacizumab × 90 days × Clear all

NCT06843447 2026-05-26

MK-5909-003

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Ovarian Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon ⚡